ReviewJournal of clinical and experimental hepatology
Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Frontiers and emerging trends in research on metabolic syndrome and metabolic dysfunction-associated fatty liver disease: a bibliometric analysis (2005-2024).Frontiers in endocrinology · 2026Pooled it
- Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals.Clinical and molecular hepatology · 2022Pooled it
- Relationship Between Frontal QRS-T Angle and Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score in Patients with Stable Angina Pectoris.Journal of clinical medicine · 2025Article
- Article
- MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk.Hepatic medicine : evidence and research · 2025Review
- Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review.Cardiovascular diabetology · 2024Review
- Machine Learning Approach for Cardiovascular Death Prediction among Nonalcoholic Steatohepatitis (NASH) Liver Transplant Recipients.Healthcare (Basel, Switzerland) · 2024Article
- Metabolic disease and the liver: A review.World journal of hepatology · 2024Review
- An international multidisciplinary consensus statement on MAFLD and the risk of CVD.Hepatology international · 2023Article
- Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study.Diabetology & metabolic syndrome · 2023Article
- Fibrosis score 4 index has an independent relationship with coronary artery diseases in patients with metabolic-associated fatty liver disease.Diabetology & metabolic syndrome · 2023Article
- The Link between NAFLD and Metabolic Syndrome.Diagnostics (Basel, Switzerland) · 2023Review
- Relationship between liver function tests & cardiovascular risk factors in stage 3-5 pre-dialysis chronic kidney disease.The Indian journal of medical research · 2022Article
- Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort.Journal of the American Heart Association · 2022Article
- Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study.PloS one · 2022Article
- Gut dysbiosis and systemic inflammation promote cardiomyocyte abnormalities in an experimental model of steatohepatitis.World journal of hepatology · 2021Article
- Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?Hepatology international · 2021Article
- An analysis of the correlation between the human apolipoprotein E gene polymorphism and lipoprotein-associated phospholipase A2.Cardiovascular diagnosis and therapy · 2020Article
- Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort.Journal of clinical medicine · 2020Article
- Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach.Canadian journal of gastroenterology & hepatology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. Patients with NAFLD are at a higher risk of developing cardiovascular disease (CVD). In fact, CVD-related mortality is more common in patients with NAFLD in comparison to liver-related mortality. This association is related to the common metabolic risk factors such as obesity, dyslipidemia, diabetes, and hypertension shared by both NAFLD and CVD, and also there is independent association of NAFLD with CVD because of risk factors such as insulin resistance, systemic inflammation, and atherogenic dyslipidemia. While there is abundant literature on association of NAFLD with CVD, there is sparse literature regarding the screening for CVD in patients with NAFLD. In the current review article, we discuss as to which patients with NAFLD to screen and how to screen for CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.